NCT00862849View on ClinicalTrials.gov

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 31, 2009

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
Diabetes Mellitus
Interventions
DRUG

Insulin Lispro

DRUG

Regular Human Insulin

DRUG

rHuPH20

Trial Locations (1)

91911

Profil Institute for Clinical Research, Inc., Chula Vista

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00862849 - Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone | Biotech Hunter | Biotech Hunter